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Jean-Christophe Tille, MD, PhD,d Ebrahim Khabiri, MD,a Mustafa Cikirikcioglu, MD, PhD, FETCS,a
Michael Möller, PhD,c and Beat H. Walpoth, MD, FAHA,a Geneva, Switzerland; and Poznan, Poland
Objective: There is a continuous search for shelf-ready small-caliber vascular prostheses with satisfactory early and late
results. Biodegradable scaffolds, repopulated by recipient’s cells regenerating a neovessel, can be a suitable option for
adult and pediatric, urgent and elective cardiovascular procedures.
Methods: This was a short-term experimental assessment of a new biodegradable vascular prosthesis for arterial replace-
ment in the pig. Eleven pigs underwent bilateral carotid artery replacement with biodegradable electrospun poly-ε-cap-
rolactone (PCL) nanoﬁber prostheses (internal diameter, 4 mm; length, 5 cm); or expanded polytetraﬂuoroethylene
(ePTFE) prostheses as control. Perioperative anticoagulation was achieved with intravenous heparin (double baseline
activated clotting time). Postoperatively, until conclusion of the study at 1 month, animals received aspirin and clopi-
dogrel daily. Transit time ﬂow was measured intraoperatively and at sacriﬁce. Doppler ultrasound (1 and 4 weeks) and
a selective carotid angiography (4 weeks) were performed to assess patency. All explanted grafts were analyzed by
histology, morphometry, and scanning electron microscopy in order to study graft-host interaction.
Results: Surgical handling and hemostasis of the new prostheses were excellent. Patency rate was 78% (7/9) for PCL
grafts, compared with 67% (4/6) for ePTFE grafts. Transit time ﬂow and Doppler ultrasound showed no signiﬁcant
changes in ﬂow and velocity or diameter over time in both groups. Both prostheses showed no detectable in vivo
compliance as compared with native carotid artery. Percent neoendothelialization was 86% for PCL and 58% for ePTFE
grafts (P [ .008). Neointima formation was equal in both grafts. More adventitial inﬁltration of macrophages, myoﬁ-
broblasts, and capillaries was seen in PCL grafts with a milder foreign-body reaction when compared with ePTFE
implants. Both grafts showed similar endoluminal thrombus formation.
Conclusions: Biodegradable, electrospun PCL grafts showed good surgical and mechanical properties, no aneurysm
formation, and similar short-term patency compared with ePTFE grafts. Rapid endothelialization and cell ingrowth
conﬁrms favorable PCL graft-recipient biological interaction. Despite good early results, long-term follow-up is required
before clinical application. (J Vasc Surg 2014;59:210-9.)
Clinical Relevance: Expanded polytetraﬂuoroethylene vascular grafts provide excellent mechanical and handling prop-
erties. However, their late postimplant performance is poor due to nonhomogeneous endothelialisation, intimal hyper-
plasia - substrates of thrombotic occlusion. Drawbacks of expanded polytetraﬂuoroethylene prostheses are connected with
their bioinertness and could be overcome by introduction of biodegradable vascular implants that provide an artiﬁcial
scaffold for complete vessel regeneration via in vivo tissue engineering. Poly-e-caprolactone prostheses have already
demonstrated satisfactory performance showing rapid and complete endothelialization, colonization by different recip-
ients’ cell and extracellular matrix reconstruction. This proves an ability of integration with the host tissues providing
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://dx.doi.org/10.1016/j.jvs.2013.03.004The shortage of autologous vascular grafts is an obstacle in
surgical revascularization ofmyocardiumor lower limbs.1 This
is mainly due to previous multiple operations in a comorbid
and aging population.2,3 Therefore, the search for the ideal
synthetic small caliber vascular graft continues.4 Currently,
clinically approved vascular substitutes are commonly used
in patients despite the suboptimal outcome of small caliber
prostheses. For example, expanded polytetraﬂuoroethylene
(ePTFE) grafts, despite excellent surgical properties, still
present a signiﬁcant percentage of thrombosis, stenosis, or
occlusion. To improve their biological compatibility,
different strategies have been developed including titanium
or pyrolytic carbon coating or endoluminal surface cell seed-
ing.5,6 However, the randomized studies were not able to
detect a real clinical advantage of those approaches.6,7
Fig 1. Biodegradable poly-ε-caprolactone (PCL) vascular graft.
Graft characteristics: inner diameter, 4 mm; length, 80 mm; wall
thickness, 500 mm; mean ﬁber diameter of 2.26 0.6 mm; porosity,
80%; maximum tensile stress of 4.8 MPa, and maximum tensile
strain of 600%. Insert: scanning electron microscope (SEM)
picture (magniﬁcation, 90) of graft transverse cross-section and
external surface.
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comes from their biological inertness that precludes inte-
gration of the prosthesis with the surrounding tissues in
the process of remodeling.8 Taking this into account, we
have been advocating the concept of in vivo tissue engi-
neering with the use of a biodegradable vascular scaffold
that, once implanted, initiates the neovessel formation
thanks to the recipient organism’s inherent regenerative
abilities.9,10,11 Unlike time- and resource-consuming
ex vivo tissue engineering for neovessel construction,
this approach is more suitable for a real clinical practice,
including frequent emergency cases.12,13
Different scaffold materials have been proposed,7,14,15
and multiple manufacturing methods have been developed.
Currently, electrospinning is one of the most popular ways
to produce 3D scaffolds for vascular prostheses.14,15 The
advantage of this process is that the resulting nanoﬁber
scaffold can increase a recipient’s biological response by
allowing contact guidance of invading host cells, thus
enhancing vessel regeneration.16 Having positive experi-
ences with electrospun poly-ε-caprolactone (PCL) nano-
ﬁber implants in the rat infrarenal abdominal aorta
replacement model,9,10,17 we decided to investigate our
vascular grafts in a porcine preclinical model of carotid
artery replacement as a step towards future human
applications.
METHODS
The experimental protocol was approved by the
Animal Experiments Ethics Committee of the University
of Geneva and the Veterinary Ofﬁce of the State of Geneva
(Switzerland; No. 1081-3271-3) and carried out in accor-
dance with the Guide for Care and Use of the Laboratory
Animals (National Research Council, Washington, DC:
National Academy Press; 1996).
Preparation of vascular grafts. The 4-mm-inner
diameter, 80-mm-long biodegradable vascular grafts
(wall thickness: 500 mm) made from PCL were obtained
by electrospinning of a solution of 15% weight:volume
PCL (Mw ¼ 80,000 g/mol; Sigma, Hamburg, Germany)
and CHCl3/EtOH (7:3 v:v; Reidel-de-Haën, Seelze,
Germany; Hänseler, Herisau, Switzerland) as previously
described in detail (Fig 1).9,10,17 All grafts had a mean
ﬁber diameter of 2.26 0.6 mm (standard error of the mean
measurements) a maximum tensile stress of 4.8 MPa, and
a maximum tensile strain of 600% (M1600; Schenk AG,
Darmstadt, Germany) after sterilization by g-radiation (25
kGy). The porosity assessed by gravimetry was 80%. PCL
vascular graft is kept in clinical grade sterile packing ready
for implanatation. Commercially available ePTFE grafts
served as controls (30 mm thru-pore, 4 mm inner diameter,
80 mm long; Atrium, Mijdrecht, The Netherlands).
Animals, anesthesia, and surgery. Eleven male land
race pigs weighing 34.2 6 4.9 kg (range, 29-45 kg) were
utilized and assigned to PCL or ePTFE groups. They
were fasted the night before surgery and received normal
food throughout the postoperative period. They were
premedicated with 3 mg/kg azaperone (Stresnil; Roche,Basel, Switzerland) and consecutively anesthetized with
2% isoﬂurane (Isoﬂurane; Abbott, Baar/Zug, Switzerland),
4 mg pancuronium bromide (Pavulon; Organon, Pfäfﬁkon,
Switzerland), and 0.5 mg/kg/min fentanyl (Fentanyl;
Sintetica, Mendrisio, Switzerland) and intubated. The
animals were ventilated (Servo Ventilator 900D; Siemens,
Erlangen, Germany) as well as monitored by the use of
three-lead electrocardiograph, SpO2, temperature, and
direct arterial and central venous blood pressure measure-
ments (Datex AS/3 cardio-monitor; Datex, Helsinki,
Finland). The animals were heparinized (10,000 IU) in
order to obtain double values of the activated clotting time
values (Hemochron 401; ITC, Edison, NJ).
The technique of graft implantation for porcine
carotid replacement has been described previously by our
group.5,18 Ten PCL grafts were implanted in ﬁve animals
bilaterally and compared with six control ePTFE grafts
that were implanted unilaterally (n ¼ 6) in six animals
from another series. A beveled (30-45) end-to-end anas-
tomosis with the use of interrupted 7-0 polypropylene
suture (Prolene; Ethicon, Neuchatel, Switzerland) was
applied (Fig 2).
Hemostasis was veriﬁed, and ﬂow control measure-
ments (see below) were performed on the native common
carotid artery (CCA) at 2 cm distance from both anasto-
moses of each prosthesis.
The wound was closed in a standard fashion with
absorbable 2-0 and 3-0 Vicryl sutures (Ethicon, Neuchatel,
Switzerland) after repeated meticulous hemostasis. The
animal was then woken up and extubated. After 1 hour of
respiratory surveillance, the pig was transferred to his box,
and consecutively 1 week after, to the farm. All animals
received a daily oral dose of aspirin (10 mg/kg) and clopi-
dogrel (3 mg/kg) during the 1 month following surgery.
Graft explantation and sacriﬁce. One month after
implantation, all animals were anesthetized as described
above. A digital subtraction angiography (Cardiac Series
9800; General Electric, Salt Lake City, Utah) of the carotid
vessels was performed. Percentual narrowing (stenosis) of
Fig 2. Implantation of poly-ε-caprolactone (PCL) prosthesis. A,
Native porcine common carotid artery after surgical preparation
(note vagus nerve indicated by the arrow). B, Native common
carotid artery is cross-clamped proximally as well as distally and
divided. The graft is beveled at the proximal end before
construction of the end-to-end anastomosis. The distal part will
be beveled just before performing the anastomosis. C, PCL graft
is implanted in carotid position with the use of interrupted
nonresorbable polyprolpylene 7-0 sutures. *Proximal side.
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compared with native proximal carotid artery diameter was
calculated according to modiﬁed North American Symp-
tomatic Carotid Endarterectomy Trial (NASCET) formula
(1-[Bx/A])  100. The wound was reopened and grafts
dissected with 1 cm of native CCA proximal and distal to
anastomosis. The implants were explanted en bloc with
long segments of native proximal and distal CCAs after
performing ﬂow studies. Grafts were ﬂushed with saline
before further processing. The animals were sacriﬁced by
intravenous potassium chloride overdose.
Physiological assessment. The ﬂow in the native
CCA was assessed intraoperatively with the use of a transit
time ﬂow (TTF) ultrasound Doppler probe (Cardio-Med
CM-4008; Medistim, Oslo, Norway) before vessel re-
placement. The test was repeated after graft implantation
on native CCA proximal and distal to the anastomosis and
the mean value was registered. The TTF assay was repeated
before graft explantation. Additionally, a conventional
transcutaneous Doppler ultrasound (GE Vingmed System
Five; General Electric) study was carried out preoperatively
to obtain internal diastolic diameter and ﬂow velocity of
the native CCA. Similar noninvasive measurements were
repeated postoperatively, at 1 week after the implantation
(under mask 4% isoﬂurane anesthesia after standard pre-
medication), and before the explantation at 1 month.
Morphological and quantitative analyses. For the
histological evaluation, explanted grafts with both anasto-
moses were ﬁxed in 4% formaldehyde for 24 hours, and
one-half of the longitudinal hemi-graft cuts were em-
bedded in parafﬁn. Four mm thick histological sections
were stained with hematoxylin-eosin, Miller-Masson forelastin and collagen deposition, and immunohistochemistry
with an anti-CD31 antibody (Santa Cruz Biotechnology
Inc, Heidelberg, Germany; PECAM-1 [M20]) for endo-
thelium and neo-angiogenesis staining. Histological slides
were numerically scanned in their totality at a 20
magniﬁcation (Mirax Midi; Carl Zeiss MicroImaging
GmbH, Jena, Germany) and quantiﬁed with an image
processing software (Mirax Viewer; Carl Zeiss Micro-
Imaging GmbH, Jena, Germany and ImageJ; U.S.
National Institutes of Health, Bethesda, Md). The
following measurements were done on the slides: percent
endothelial coverage (percentage of the graft luminal
surface covered by endothelial cells), percent transmural
cellular ingrowth (percentage of the graft area densely
penetrated by host cells from the adventitial tissue towards
the luminal side), intimal hyperplasia coverage (percentage
of the graft length covered with intimal hyperplasia),
average intimal hyperplasia (IH) thickness (in mm, area
between the endothelial layer and the graft luminal surface,
normalized by the neointima length), and thrombus
coverage (percentage of the graft length covered with
thrombus or microthrombus). In addition, scanning elec-
tron microscopy (SEM) was used to image the other one-
half of the longitudinal sections of explanted grafts (Philips
XL20 SEM; Philips, Eindhoven, The Netherlands).
Samples were prepared with standard dehydration and
gold coating techniques.
Statistics. All the results were expressed as mean 6
standard error. Intergroup comparisons were performed
with the use of Mann-Whitney U test, while for intra-
group repeated measure comparisons a sign test was
utilized. Fisher exact test was used for binary variables.
Totally occluded grafts were excluded from the compari-
sons concerning endothelialization, IH, and/or thrombus
coverage. A two-tailed P value less than .05 was considered
signiﬁcant in all tests. P values between .05 and .1 marked
a trend towards a statistical signiﬁcance.RESULTS
Arterial replacement, animal survival, and graft
patency. Both PCL and ePTFE grafts showed excellent
surgical properties during implantation. They were easy
to trim, and good suture retention enabled a secure bev-
eled anastomosis. For PLC implants, no peri-stitch
bleeding was observed, unlike ePTFE grafts. However,
PCL grafts showed transient transprosthetic leakage after
reestablishing the ﬂow through the vessel. This leakage
concerned the whole length of the implant and ceased
rapidly. In the two animals with excessive heparinization
(activated clotting time values over 1000 m), the trans-
prosthetic blood leakage had to be stopped with the use
of hemostatic compresses. Incisions and sutures performed
directly on the PCL graft resulted in good hemostasis
(see below). Both graft types showed no radial compliance
in comparison to the native carotid arteries; the systolic-
diastolic dilatation was not visually present as for the
native CCA, also conﬁrmed by echographic studies.
Fig 3. Angiographic study of the implanted grafts after 4 weeks
(antero-posterior projection).A, Patent poly-ε-caprolactone (PCL)
graft. B, Patent expanded polytetraﬂuoroethylene (ePTFE) graft.
No anastomotic stenosis or aneurysm formation visible. *Proximal
anastomosis; #distal anastomosis.
Table. Quantitative angiography results at 1 month
follow-up after porcine carotid artery replacement
No.
NASCET, %
Proximal
anastomosis Middle graft
Distal
anastomosis
PCL graft 7 7.93 6 5.27 7.83 6 7.04 8.13 6 3.97
ePTFE graft 4 13.46 6 3.13 10.89 6 10.79 13.24 6 6.80
P valuea – .16 .50 .21
ePTFE, Expanded polytetraﬂuoroethylene; ePTFE graft, control ePTFE
graft; NASCET, North American Symptomatic Carotid Endarterectomy
Trial; PCL, poly-ε-caprolactone; PCL graft, biodegradable PCL graft.
Percentual narrowing of proximal anastomosis, middle graft, and distal
anastomosis compared with native proximal carotid artery diameter calcu-
lated with the use of NASCET formula: (1[Bx/A])  100 where A stands
for proximal carotid artery diameter (5 cm before the proximal anastomosis)
and Bx for diameter of investigated part of the graft. Totally occluded graft
excluded from analysis.
aMann-Whitney U test.
Fig 4. Intraoperative physiological assessment of studied vascular
grafts. Blood ﬂow through the carotid artery measured with
ultrasound transit time ﬂow (TTF) method. Intergroup com-
parisons: *, **, *** - all statistically nonsigniﬁcant. Intragroup,
repeated measure comparisons: poly-ε-caprolactone (PCL) graft:
#-#, ##-## - both statistically nonsigniﬁcant; expanded poly-
tetraﬂuoroethylene (ePTFE) graft: $-$, $$-$$ - both statistically
nonsigniﬁcant. Occluded grafts excluded from analysis.
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two pigs from the PCL group, two intraoperative occlu-
sions occurred. One perioperative occlusion was noted
despite good technical conditions for the anastomosis.
After its detection, an immediate thrombectomy was
carried out; however, without durable result. The second
occlusion was due to an evident technical failure, and
therefore this graft was excluded from the analysis (PCL
group; n ¼ 9). Additionally, one late occlusion was
detected at the end of the study. Thus, overall late patency
rate for the PCL group was 77.8% (7/9), compared with
66.7% (4/6) patency rate of the ePTFE group resulting
from two late occlusions seen at the end of the study
(P ¼ .7). Patency of remaining grafts was conﬁrmed by
angiography (Fig 3). Quantitative angiographic resultsaccording to NASCET formula calculations are presented
in the Table.
Physiologic studies
Intraoperative TTF ﬂow measurement. Initial ﬂow
though the carotid artery was similar for both groups.
Flow decreased postoperatively in PCL and ePTFE grafts,
but this drop was not statistically signiﬁcant. At 4 weeks,
ﬂow rates in both implants were still similar (Fig 4).
Doppler ultrasound. Ultrasound Doppler studies
showed similar ﬂow velocity through the native carotid
vessels, which did not change and were equal after the
interposition of both PCL and ePTFE grafts observed at
1 week. After 4 weeks, the ﬂow velocity for both groups
slightly increased, but without reaching statistical signiﬁ-
cance (Fig 5, A).
Native carotid artery internal diastolic diameter was
similar preoperatively in both studied groups. It did not
change signiﬁcantly after the implantation of vascular grafts
and was constant until the end of the study. There was no
difference between PCL and ePTFE grafts at 1 and 4 weeks
after the operation (Fig 5, B).
Histology and morphometry. The median endothe-
lization of PCL grafts was 86% (range, 68%-95%) and was
signiﬁcantly higher than in the ePTFE group at 58% (range,
18%-60%; P ¼ .008; Fig 6, A). Neoendothelization of the
luminal side was conﬁrmed by CD31 staining (Figs 7, A and
B). The median percent IH coverage was more pronounced
in the PCL group (58%), but was not signiﬁcantly different
than in the control group (30%; P ¼ .26; Figs 6, B and 7, C
and D). In PCL grafts, the IH was usually composed, in
both groups, of spindle shape cells with no calciﬁcations
Fig 5. Percutaneous ultrasound study of implanted vascular grafts.
A,Maximal ﬂow velocity through the carotid artery measured with
percutaneous Doppler ultrasound. Intergroup comparisons: *, **,
*** - all statistically nonsigniﬁcant. Intragroup, repeated measure
comparisons: poly-ε-caprolactone (PCL) graft: #-#, ##-## - both
statistically nonsigniﬁcant; expanded polytetraﬂuoroethylene
(ePTFE) graft: $-$, $$-$$ - both statistically nonsigniﬁcant. B,
Carotid artery internal diastolic diameter over time. Intergroup
comparisons: *, **, *** - all statistically nonsigniﬁcant. Intra-
group, repeated measure comparisons: PCL graft: #-#, ##-## -
both statistically nonsigniﬁcant; ePTFE graft: $-$, $$-$$ - both
statistically nonsigniﬁcant. Occluded grafts excluded from analysis.
JOURNAL OF VASCULAR SURGERY
214 Mrówczynski et al January 2014present. The IH was more pronounced close to the anas-
tomotic sites in all studied grafts. The intergroup difference
in average thickness of IH was not statistically signiﬁcant,
but higher maximal values of this parameter were found in
the PCL group (198 6 104 vs 159 6 57 mm2/mm). There
was no signiﬁcant difference concerning the percent of
thrombus coverage between both groups (P ¼ .22), but
again the PCL group showed higher maximal values (Figs 6,
C and 7, E and F). Thrombus presence was related to the
appearance of a prosthetic kink in the two grafts from the
PCL group, and for one, it resulted in total occlusion.
In the PCL group postoperatively, cellular graft inﬁltra-
tion after 1 month consisted of macrophages andﬁbroblasts within the whole cellular invasion area, as well
as giant cells at the adventitia. A few lymphocytes were
found in ePTFE grafts. The percent transmural cellular
ingrowth was higher in the PCL group (44%) compared
with ePTFE grafts (5%), showing statistical signiﬁcance
(P ¼ .001; Fig 6, D). Cellular graft inﬁltration in PCL
grafts was accompanied by moderate neoangiogenesis
reaching the three-quarter thickness of the implant, while
the ePTFE group showed only a scarce number of superﬁ-
cially penetrating neocapillaries in the adventitia, conﬁrmed
by CD31 immunostaining (Fig 7, G and H). No elastin
depositions were found in any type of vascular graft within
IH or inside the implant. Only small amounts of collagen
were visible in PCL implants within the body of the graft.
The ﬁbrous peri-graft reaction, with a mild chronic
inﬂammatory lymphocytic reaction, was noted for PCL
and ePTFE prostheses alike. In both, the presence of few
eosinophils, but no neutrophils, was observed. The forma-
tion of a thick and well-pronounced ﬁbrous capsule char-
acterized ePTFE vascular grafts compared with PCL
(Fig 7, E and F).
Scanning electron microscopy. The randomly ori-
ented micro- and nanoﬁbers of electrospun PCL implants
are shown in Fig 8, A. The SEM picture 1 month after
the explantation was consistent with histological studies of
the endothelium. On both graft types, the endothelium
coverage was not complete, predominantly in the central
part where it was patchy. Nonendothelialized parts were
covered by protein, possibly ﬁbrin layer (Fig 8, C and F).
Microthrombi were observed in PCL and ePTFE implants
(Fig 8, D). At the anastomosis, vascular endothelial cell
columns were oriented perpendicularly to blood ﬂow
direction, which is contrary to the pattern of endothelium
lining of native arteries (Fig 8, E).
DISCUSSION
The current in vivo study in pigs shows that an electro-
spun small diameter biodegradable PCL vascular graft is
comparable to an ePTFE implant in terms of surgical
friendliness in creating end-to-end anastomosis and hemo-
static properties. Similarly, satisfactory mechanical charac-
teristics of PCL implants were proven by good suture
retention and the absence of aneurysmal dilatation at 4
weeks postoperatively. This can be attributed to slow
in vivo degradation of PLC scaffolds that provide a resis-
tance to structural deterioration.10,19
The patency rate of PCL grafts was similar to that of
ePTFE grafts and is comparable to other studies using
ePTFE implants in pigs in the carotid artery position.5,18
A similar 67% patency of a regular 4-mm graft implanted
in a femoro-popliteal position was reported by Heise.20
On the contrary, lower patency rates (50%) were observed
in the setting of a porcine carotid arteriovenous graft
model.21 We have already demonstrated the excellent
patency rate of PCL electrospun vascular implants in a rat
model of infrarenal abdominal aorta replacement.10,17
However, the current model reﬂects better the situation
found in small caliber vessels.
Fig 6. Morphometric analyses of the grafts after 4 weeks: endothelial coverage, neointimal hyperplasia coverage,
thrombus coverage, and percent transmural cellular ingrowth according to graft type. A, Percent of endothelial
coverage, signiﬁcant intergroup difference (*P ¼ .008). B, Percent of neointimal hyperplasia coverage (P ¼ NS). C,
Percent of thrombus/microthrombus coverage (P ¼ NS). D, Percent of transmural cellular ingrowth (*P ¼ .001).
Occluded grafts excluded from the analysis. ePTFE, Expanded polytetraﬂuoroethylene; PCL, poly-ε-caprolactone.
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use of noninvasive ultrasound techniques, similar to other
groups,20 and angiography was carried out only at the
conclusion of the study.21 In order to reduce the number
of necessary anesthesia procedures, the animals were exam-
ined only once in the interim period between the surgical
procedure and sacriﬁce. The time of late failure established
in our study is between 1 and 4 weeks, which is comparable
with other investigations in pigs.21 However, the late
occlusion caused by thrombosis in our series was connected
with a mechanical kink, not, for example, by the IH devel-
opment leading to critical stenosis.
The favorable patency rate of PCL and ePTFE grafts
could be attributed to the administration of the aspirin
and clopidogrel combination throughout the whole study
period, which is known to improve the outcome in
pigs.21-23 This is similar to the medical therapy in humans
operated on for different vascular reasons. However, this
treatment does not inﬂuence the rate of endothelialization
nor does it decrease the formation of unsolicited intimalhyperplasia as seen in different animals in the case of ePTFE
implants.24
This study demonstrates a rapid endothelialization
of PCL implants, reaching a mean of 86% and a maximum
of 95% of the graft surface, signiﬁcantly better than in
ePTFE vascular grafts. This proves the better biocompati-
bility of our graft. However, some nonendothelialized
zones were visible close to the anastomotic area. This
could have been caused by the turbulence at the anasto-
mosis due to a compliance mismatch (Fig 8, F). The better
endothelialization of PCL grafts is based on a micro-/nano-
architecture that resembles extracellular matrix and allows
faster cell migration.25 The latter is hampered in ePTFE
grafts.26-28
As early occlusions can be explained by coagulation
sequels on a nonbiocompatible surface, late failures are
usually attributed to intimal hyperplasia,21 which is ubiqui-
tously present in different animal models and in human clin-
ical settings.24,29,30 During the short observation time of the
study, we found no evidence of clinically signiﬁcant intimal
Fig 7. Histopathological ﬁndings according to vascular implant type. A, C, E, G, Poly-ε-caprolactone (PCL). B, D, F,
H, Expanded polytetraﬂuoroethylene (ePTFE). A and B, CD31 immunostaining shows endoluminal endothelial
coverage (arrow) that was more complete in PCL (A) grafts than in ePTFE (B) implants (magniﬁcation, 400). C and
D, Neointimal hyperplasia (arrows) was present in both types of implants (magniﬁcation, 200). E and F, Multiple
microthrombi (arrow) were present in both PCL and ePTFE vascular grafts (magniﬁcation, 20).G andH, Neovessels
in the graft (arrows) were more abundant in PCL implants in comparison to ePTFE prostheses, where only single
capillaries were invading superﬁcially the adventitial surface of the graft (magniﬁcation, 20). #Lumen of the prosthesis;
^Adventitial side of the prosthesis.
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ciency of PCL grafts that was seen at the end of the study, we
noted the increase of the transprosthetic maximal ﬂow
velocity at this time point. The change was not statistically
signiﬁcant, but it could be attributed to the IH progression
visible in the histomorphometry. Obviously, this discreet
lumen decrease could not be reﬂected in the ultrasoundstudy, but it is well known that even a moderate layer of
IH can be a cause of popliteal bypass occlusion.30 Another
explanation could be the presence of thrombus depositions
detected in both studied grafts.
The IH develops as a pathophysiological adaptation
to increased cyclic intramural tension in two phases.29,31
The early phase includes cell proliferation within the ﬁrst
Fig 8. Scanning electron microscope (SEM) picture of poly-ε-caprolactone (PCL) vascular grafts. A, View of the
endoluminal surface of nonimplanted PCL (magniﬁcation, 180). B, Complete endothelialization of PCL graft
(magniﬁcation, 760). C, Cross-section of PCL implant (*), lumen of the graft (#). Protein and endothelial coverage
are visible on the endoluminal surface (magniﬁcation, 760). D, Presence of the microthrombus on the endoluminal
surface of the neoendothelialized PCL graft (magniﬁcation, 750). E, Proximal anastomosis area of PCL graft.
l, Longitudinal disposition of the native carotid artery endothelium; p, perpendicular neoendothelium.
*Nonendothelialized zone (magniﬁcation, 70). F, PCL graft transition zone between endothelialized zone and
protein-covered area. *Nonendothelialized zone (magniﬁcation, 390).
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matrix.31 The IH formation was similar in both assessed
vascular implants up to 4 weeks of observation. Thus, the
most probable explanation of this ﬁnding is the compliance
mismatch between the native carotid artery and both types
of artiﬁcial grafts used in this study.32 The endothelium
covering the anastomotic site is subjected to a turbulent
ﬂow and an increased pressure, as its prosthetic basement
cannot follow the diastolic-systolic vasomotion. This results
in endothelial dysfunction contributing to IH.33 Different
methods of IH prevention have been developed, including
the most effective (eg, hirudin and iloprost coating of
ePTFE grafts)20 or regional cytostatic drug release (pacli-
taxel) within PCL electrospun vascular grafts, resulting in
signiﬁcant reduction of IH.17
This study documented an abundant cellular invasion
into the body of PCL scaffold that was accompanied byneoangiogenesis, contrary to ePTFE prostheses. It conﬁrms
the thesis that the PCL nanoﬁber structure can provide
good environment for cellular repopulation.14,15 Our study
encompasses an early phase of the prosthetic cellular inva-
sion, during 1 month. Up to this moment, only ﬁbroblasts
and macrophages were seen inside the graft and giant cells in
the adventitia. This can be explained by the early ongoing
vessel regeneration when no other cell lines, including the
most solicited smooth muscle cells, are detectable. Another
reason is the absence of the appropriate extra-cellular matrix
(we noticed only minimal collagen secretion, no elastin was
present) and regional compliance abnormality related to the
stiffness of our graft. In fact, different matrix compliances
can direct the differentiation of cells into different lineages.34
PCL electrospun vascular grafts showed minimal ﬁbrous
peri-graft reaction with mild chronic inﬂammation. This
favorable ﬁnding certainly facilitates further graft inﬁltration
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formation of a thick ﬁbrous capsule.
Study limitations. This preliminary study is limited
by a short period of observation that precludes an insight
into late post-implantation phenomena. However, this
short time assessment yields important information for the
early phase of vascular graft implantation for a living
organism e prosthesis interaction e an acute event is fol-
lowed by a vulnerable period of healing.
Another bias of our study is the young age of our
experimental animals. It is known that older patients
show a diminished regeneration capacity in comparison
to children.35 The length of the vascular grafts used is
signiﬁcantly shorter than the lengths of bypasses routinely
used in man for peripheral vascular surgery and myocardial
revascularization.
The current study has a potential suboptimal control
group coming from another study. The main reason is an
active institutional introduction and promotion of the 3R
Rule (Reduction, Reﬁnement, Replacement) in animal
experimentation in order to reduce the number of animals
used as pioneered by Russell and Burch in the late 1950s
(3R Research Foundation Switzerland; http://www.
forschung3r.ch/index_fr.html). Implantation of ePTFE
and PCL grafts in the same animal (self-control) would
certainly be the best option. However, control group pigs
were coming from the same animal provider, and the
operations were performed by the same surgical team in
identical surgical experimental conditions.
Despite the above-mentioned limitations, our model
seems to be a valid platform for small caliber PCL vascular
graft testing thanks to easiness of implementation and
sensitivity to thrombosis. In this light, our electrospun
PCL prosthesis performed promisingly, which is reﬂected
in good hemodynamics and rapid neoendothelial coverage.
CONCLUSIONS
Biodegradable small caliber, electrospun PCL grafts
showed good mechanical and surgical properties, no aneu-
rysm formation, and similar short-term patency compared
with ePTFE grafts. Rapid endothelialisation and cell
ingrowth conﬁrms the hypothesis of in vivo vascular tissue
engineering. Despite excellent early results, long-term
follow-up is required before clinical application.
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